What do you do for a living? keelanelli capsules
Xeljanz, approved last November for rheumatoid arthritis,had second quarter sales of $22 million. But some industryanalysts expect it to eventually capture annual sales of $1billion or more, as an alternative to injectable biotecharthritis drugs like Enbrel and Abbott Laboratories Inc's Humira that have their own side effect issues.
|